Literature DB >> 26064294

Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis.

Renfan Xu1, Anyu Tao1, Shasha Zhang2, Youbin Deng1, Guangzhi Chen2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) generally has a relatively favorable clinical course; however, non-alcoholic steatohepatitis (NASH) was much more frequently progresses to cirrhosis and hepatocellular carcinoma. We performed a systematic review and meta-analysis of clinical trials to examine the effects of vitamin E supplementation in improving liver histology in NASH. We performed a comprehensive search of the PubMed, Embase and Cochrane databases through October 2014. Weighted mean differences (WMDs) and their respective 95% confidence intervals (CIs) were calculated to assess the efficacy of vitamin E in improving liver histological scores by using fixed effects or random effects. Standard methods were performed to explore statistical heterogeneity and publication bias. Compared with controls, vitamin E supplementation significantly improved all histological parameters, including steatosis (WMD = -0.62, 95% CI: -0.95, -0.77, P = 0.0002), hepatocyte ballooning (WMD = -0.30, 95% CI: -0.56, -0.04, P = 0.03), lobular inflammation (WMD = -0.39, 95% CI: -0.67, -0.11, P = 0.007) and fibrosis (WMD = -0.39, 95% CI: -0.72, -0.06, P = 0.02). Our analysis also indicated the absence of publication bias between NASH and Vitamin E intake. This meta-analysis indicates that vitamin E supplementation had a significant and positive effect in the improvement of steatosis, ballooning degeneration, lobular inflammation and fibrosis in patients with NASH.

Entities:  

Keywords:  Non-alcoholic steatohepatitis; histological parameters; meta-analysis; vitamin E

Year:  2015        PMID: 26064294      PMCID: PMC4443128     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  34 in total

1.  Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.

Authors:  J E Lavine
Journal:  J Pediatr       Date:  2000-06       Impact factor: 4.406

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 3.  Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Shelley E Keating; Daniel A Hackett; Jacob George; Nathan A Johnson
Journal:  J Hepatol       Date:  2012-03-10       Impact factor: 25.083

4.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

Authors:  D Moher; B Pham; A Jones; D J Cook; A R Jadad; M Moher; P Tugwell; T P Klassen
Journal:  Lancet       Date:  1998-08-22       Impact factor: 79.321

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

Review 7.  Antioxidants as therapeutic agents for liver disease.

Authors:  Ashwani K Singal; Sarat C Jampana; Steven A Weinman
Journal:  Liver Int       Date:  2011-07-29       Impact factor: 5.828

8.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

Authors:  Leon A Adams; Schuyler Sanderson; Keith D Lindor; Paul Angulo
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

9.  Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis.

Authors:  Nghi Phung; Natasha Pera; Geoffrey Farrell; Isabelle Leclercq; Jing Yun Hou; Jacob George
Journal:  Int J Mol Med       Date:  2009-08       Impact factor: 4.101

Review 10.  Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis.

Authors:  Kenneth Cusi
Journal:  Clin Liver Dis       Date:  2009-11       Impact factor: 6.126

View more
  9 in total

1.  Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand.

Authors:  Bunchai Chongmelaxme; Pochamana Phisalprapa; Ratree Sawangjit; Piyameth Dilokthornsakul; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

Review 2.  Non-alcoholic Fatty Liver Disease: A Clinical Update.

Authors:  Joseph M Pappachan; Shithu Babu; Babu Krishnan; Nishal C Ravindran
Journal:  J Clin Transl Hepatol       Date:  2017-07-26

3.  Recommendations for the management of non-alcoholic fatty liver disease (NAFLD).

Authors:  Krzysztof Tomasiewicz; Robert Flisiak; Waldemar Halota; Jerzy Jaroszewicz; Dariusz Lebensztejn; Wojciech Lisik; Piotr Małkowski; Małgorzata Pawłowska; Anna Piekarska; Krzysztof Simon; Olga Tronina
Journal:  Clin Exp Hepatol       Date:  2018-09-10

Review 4.  Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease.

Authors:  Alejandro Campos-Murguía; Astrid Ruiz-Margáin; José A González-Regueiro; Ricardo U Macías-Rodríguez
Journal:  World J Gastroenterol       Date:  2020-10-21       Impact factor: 5.742

Review 5.  An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents.

Authors:  Vinka Rupcic Rubin; Kristina Bojanic; Martina Smolic; Jurica Rubin; Ashraf Tabll; Robert Smolic
Journal:  J Clin Transl Hepatol       Date:  2021-01-04

6.  Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis.

Authors:  Benedikt Simbrunner; Georg Semmler; Alexander Stadlmann; Bernhard Scheiner; Philipp Schwabl; Rafael Paternostro; Theresa Bucsics; David Bauer; Ernst Eigenbauer; Matthias Pinter; Albert-Friedrich Stättermayer; Peter Quehenberger; Rodrig Marculescu; Michael Trauner; Mattias Mandorfer; Thomas Reiberger
Journal:  Hepatol Int       Date:  2020-12-08       Impact factor: 6.047

7.  Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).

Authors: 
Journal:  Eat Weight Disord       Date:  2021-12-16       Impact factor: 3.008

Review 8.  Management of nonalcoholic fatty liver disease in the Middle East.

Authors:  Faisal M Sanai; Faisal Abaalkhail; Fuad Hasan; Muhammad Hamed Farooqi; Nawal Al Nahdi; Zobair M Younossi
Journal:  World J Gastroenterol       Date:  2020-07-07       Impact factor: 5.742

9.  Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model.

Authors:  Julie Hviid Klaebel; Mia Skjødt; Josephine Skat-Rørdam; Günaj Rakipovski; David H Ipsen; Anne Marie V Schou-Pedersen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Nutrients       Date:  2019-11-19       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.